移植片対宿主病（GvHD）治療の世界市場

移植片対宿主病（GvHD）治療の世界市場は2030年までに45億米ドルに到達

2024年に29億米ドルと推定される移植片対宿主病（GvHD）治療の世界市場は、2024年から2030年にかけてCAGR 7.3%で成長し、2030年には45億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるカルシニューリン阻害剤は、CAGR 9.0%を記録し、分析期間終了時には19億米ドルに達すると予測されます。抗増殖剤セグメントの成長率は、分析期間中CAGR 5.0%と推定されます。

米国市場は8億80万米ドルと推定、中国はCAGR 11.7％で成長すると予測

米国の移植片対宿主病（GvHD）治療市場は、2024年に8億80万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 11.7%で推移し、2030年には予測市場規模9億6,050万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.5%と7.2%と予測されています。欧州では、ドイツがCAGR 4.8%で成長すると予測されています。

世界の移植片対宿主病（GvHD）治療市場- 主要動向と促進要因のまとめ

移植片対宿主病（GvHD）治療が移植医療で注目される理由とは？

移植片対宿主病（GvHD）は、ドナーの免疫細胞がレシピエントの組織を攻撃する同種造血幹細胞移植（HSCT）の最も困難な合併症の一つです。白血病、リンパ腫、遺伝性疾患の治療のために幹細胞移植や骨髄移植が一般的になるにつれて、効果的なGvHD治療戦略の必要性が高まっています。免疫抑制療法や標的生物学的製剤の進歩は、この病態を管理し、患者の転帰を改善する上で重要な役割を果たしています。

GvHD治療における最近の技術革新は、バイオマーカーや遺伝子プロファイリングを利用して疾患の重症度を予測し、それに応じて治療を調整する個別化医療のアプローチに重点を置いています。JAK阻害剤、モノクローナル抗体、間葉系幹細胞（MSC）などの細胞療法の開発により、治療の展望が広がり、急性および慢性GvHD患者に新たな希望をもたらしています。免疫調節と新規治療標的に関する継続的な調査により、GvHD管理はより効果的で毒性の少ない治療レジメンへと進化しています。

どのような医学的進歩がGvHD治療法の開発を牽引しているのか？

コルチコステロイドやカルシニューリン阻害剤を含む免疫抑制剤は、依然としてGvHDの標準的な第一選択治療です。しかし、ステロイド不応性の症例の出現により、代替療法の必要性が高まっています。JAK阻害剤（ルキソリチニブ）のような新しい薬剤クラス別は、難治性GvHD患者の炎症を抑え、免疫応答を調節する上で有望な結果を示しています。さらに、IL-2受容体拮抗薬やT細胞枯渇戦略が、GvHDの進行を予防・制御するために検討されています。

細胞療法は重症GvHDを治療する新しいアプローチとして注目されています。間葉系幹細胞（MSC）は、宿主組織に対するドナー免疫細胞の攻撃を抑制する免疫調節作用を示し、再生治療としての可能性を提供しています。さらに、CRISPRのような遺伝子編集技術は、抗腫瘍効果を維持しながらGvHDのリスクを低減するドナー移植片の改変を開発するために研究されています。このような免疫療法の進歩は、GvHDの管理方法を変え、移植を受けた患者の生存率と生活の質の両方を向上させています。

GvHD治療における最新のイノベーションとは？

GvHD治療における精密医療の統合は、疾患の重症度と治療反応を予測するバイオマーカーの同定につながりました。リキッドバイオプシー技術とサイトカインプロファイリングは、臨床医が個々の患者に合わせた治療戦略を立てるのに役立っており、不必要な広域免疫抑制への曝露を最小限に抑えています。

薬剤開発の発展により、GvHDの進行に関与する主要な炎症経路を標的とする次世代の生物学的製剤が登場しました。ROCK阻害剤やスフィンゴシン-1-リン酸受容体モジュレーターのような標的治療薬は、罹患組織への免疫細胞の浸潤を防ぐ能力を試験中です。さらに、AIを活用した創薬により、新たなGvHD治療薬候補の開発が加速しており、より迅速かつ的確な治療法の進歩が期待されています。

GvHD治療市場の成長を促進している要因は何か？

GvHD治療市場の成長は、幹細胞移植手術の増加、ステロイド不応性GvHD症例の発生率の上昇、標的免疫療法の進歩によってもたらされます。がんや自己免疫疾患のために造血幹細胞移植を受ける患者が増えるにつれて、効果的なGvHD予防・治療オプションに対する需要が高まり続けています。

さらに、新規免疫抑制剤や生物学的製剤に対する製薬企業の投資によって治療の選択肢が広がり、GvHDの長期的な管理が向上しています。バイオマーカー主導の精密医療の役割の増大も市場を形成し、より個別化された効果的な治療レジメンを可能にしています。さらに、政府の資金援助と臨床研究イニシアティブにより、新たなGvHD治療薬の承認と商業化が加速しており、市場の持続的成長が確実なものとなっています。

セグメント

臓器移植免疫抑制薬クラス（カルシニューリン阻害薬、抗増殖薬、mTOR阻害薬、ステロイド、薬剤クラス別）;臓器移植免疫抑制薬移植（腎臓、肝臓、心臓、肺、膵臓、その他の移植タイプ）

調査対象企業の例

• AbbVie Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Bristol Myers Squibb
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Incyte Corporation
• Jazz Pharmaceuticals plc
• Johnson & Johnson Services Inc.
• Merck & Co., Inc.
• Mesoblast Limited
• Novartis AG
• Osiris Therapeutics, Inc.
• Pfizer Inc.
• Sanofi SA
• Syndax Pharmaceuticals
• Takeda Pharmaceutical Company Ltd.
• Tonix Pharmaceuticals

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Graft Versus Host Disease (GvHD) Treatment Market to Reach US$4.5 Billion by 2030

The global market for Graft Versus Host Disease (GvHD) Treatment estimated at US$2.9 Billion in the year 2024, is expected to reach US$4.5 Billion by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Calcineurin Inhibitors, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Antiproliferative Agents segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$800.8 Million While China is Forecast to Grow at 11.7% CAGR

The Graft Versus Host Disease (GvHD) Treatment market in the U.S. is estimated at US$800.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$960.5 Million by the year 2030 trailing a CAGR of 11.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Graft Versus Host Disease (GvHD) Treatment Market - Key Trends & Drivers Summarized

Why Is Graft Versus Host Disease (GvHD) Treatment a Growing Focus in Transplant Medicine?

Graft versus host disease (GvHD) remains one of the most challenging complications of allogeneic hematopoietic stem cell transplantation (HSCT), where the donor’s immune cells attack the recipient’s tissues. As stem cell and bone marrow transplants become more common for treating leukemia, lymphoma, and genetic disorders, the need for effective GvHD treatment strategies has increased. Advances in immunosuppressive therapies and targeted biologics have played a crucial role in managing the condition and improving patient outcomes.

Recent innovations in GvHD treatment have focused on personalized medicine approaches, utilizing biomarkers and genetic profiling to predict disease severity and tailor therapies accordingly. The development of JAK inhibitors, monoclonal antibodies, and cellular therapies such as mesenchymal stem cells (MSCs) has expanded the treatment landscape, offering new hope for patients with acute and chronic GvHD. With continued research into immune modulation and novel therapeutic targets, GvHD management is evolving toward more effective and less toxic treatment regimens.

Which Medical Advances Are Driving the Development of GvHD Therapies?

Immunosuppressive drugs, including corticosteroids and calcineurin inhibitors, remain the standard first-line treatment for GvHD. However, the emergence of steroid-refractory cases has driven the need for alternative therapies. New drug classes, such as JAK inhibitors (ruxolitinib), have shown promising results in reducing inflammation and modulating immune responses in refractory GvHD patients. Additionally, IL-2 receptor antagonists and T-cell depletion strategies are being explored to prevent and control GvHD progression.

Cellular therapies have gained attention as a novel approach to treating severe GvHD. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects that help suppress donor immune cell attacks on host tissues, offering potential as a regenerative treatment. Additionally, gene-editing technologies such as CRISPR are being investigated to develop donor graft modifications that reduce the risk of GvHD while preserving anti-tumor effects. These advancements in immune therapy are transforming the way GvHD is managed, improving both survival rates and quality of life for transplant recipients.

What Are the Latest Innovations in GvHD Treatment?

The integration of precision medicine in GvHD treatment has led to the identification of biomarkers that predict disease severity and therapeutic response. Liquid biopsy techniques and cytokine profiling are helping clinicians tailor treatment strategies for individual patients, minimizing unnecessary exposure to broad-spectrum immunosuppression.

Advancements in drug development have introduced next-generation biologics that target key inflammatory pathways involved in GvHD progression. Targeted therapies such as ROCK inhibitors and sphingosine-1-phosphate receptor modulators are being tested for their ability to prevent immune cell infiltration into affected tissues. Additionally, AI-driven drug discovery is accelerating the development of new GvHD treatment candidates, ensuring faster and more precise therapeutic advancements.

What Factors Are Fueling the Growth of the GvHD Treatment Market?

The growth in the GvHD treatment market is driven by increasing stem cell transplant procedures, rising incidence of steroid-refractory GvHD cases, and advancements in targeted immunotherapy. As more patients undergo hematopoietic stem cell transplants for cancer and autoimmune diseases, the demand for effective GvHD prevention and treatment options continues to rise.

Additionally, pharmaceutical investments in novel immunosuppressive drugs and biologics have expanded treatment choices, offering better long-term management of GvHD. The increasing role of biomarker-driven precision medicine is also shaping the market, enabling more personalized and effective treatment regimens. Furthermore, government funding and clinical research initiatives are accelerating the approval and commercialization of new GvHD therapies, ensuring sustained market growth.

SCOPE OF STUDY:

The report analyzes the Graft Versus Host Disease (GvHD) Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Organ Transplant Immunosuppressant Drug Class (Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids, Other Drug Classes); Organ Transplant Immunosuppressant Drugs Transplant (Kidney, Liver, Heart ,Lung, Pancreas, Other Transplant Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• AbbVie Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Bristol Myers Squibb
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Incyte Corporation
• Jazz Pharmaceuticals plc
• Johnson & Johnson Services Inc.
• Merck & Co., Inc.
• Mesoblast Limited
• Novartis AG
• Osiris Therapeutics, Inc.
• Pfizer Inc.
• Sanofi SA
• Syndax Pharmaceuticals
• Takeda Pharmaceutical Company Ltd.
• Tonix Pharmaceuticals

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Graft Versus Host Disease (GvHD) Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growing Incidence of Hematopoietic Stem Cell Transplants Drives Demand for GvHD Treatments
  • Biologics and Targeted Therapies Strengthen the Business Case for Advanced GvHD Treatment Options
  • Rising Research Funding and Clinical Trials Activity Expand Pipeline and Market Opportunities
  • Increased Use of Prophylactic Therapies Throws the Spotlight on Preventive GvHD Strategies
  • CAR-T and Cell Therapy Advancements Generate New Demand for GvHD Management Solutions
  • Personalized Medicine Trends Accelerate Adoption of Biomarker-Based GvHD Diagnostics
  • High Mortality and Morbidity Rates Associated with Chronic GvHD Sustain Clinical Focus
  • Immunosuppressive Drug Advancements Drive Shift from Broad to Selective GvHD Treatments
  • Rising Adoption of Real-World Evidence in Clinical Evaluation Supports Market Validation
  • Health Insurance Coverage Expansion for Cell Therapy Drives Access to GvHD Treatment
  • Regulatory Harmonization Across Regions Simplifies Global Product Launches
  • Biotech M&A Activity Throws the Spotlight on GvHD Pipeline Consolidation
  • Telemedicine Integration in Post-Transplant Care Expands Patient Access to GvHD Monitoring
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Graft Versus Host Disease (GvHD) Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Graft Versus Host Disease (GvHD) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Calcineurin Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Calcineurin Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Calcineurin Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Antiproliferative Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Antiproliferative Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Antiproliferative Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for mTOR Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for mTOR Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for mTOR Inhibitor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Steroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Steroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Steroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Pancreas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Pancreas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Pancreas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Transplant Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Transplant Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Transplant Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Kidney by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Kidney by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Kidney by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Liver by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Heart by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Heart by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Heart by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Lung by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Graft Versus Host Disease (GvHD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• JAPAN
  • Graft Versus Host Disease (GvHD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• CHINA
  • Graft Versus Host Disease (GvHD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 56: China Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• EUROPE
  • Graft Versus Host Disease (GvHD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Graft Versus Host Disease (GvHD) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Europe 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• FRANCE
  • Graft Versus Host Disease (GvHD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 71: France Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: France Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: France 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 74: France Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: France Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: France 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• GERMANY
  • Graft Versus Host Disease (GvHD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 77: Germany Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Germany Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Germany 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 80: Germany Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Germany Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Germany 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 83: Italy Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Italy Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Italy 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 86: Italy Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Italy Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Italy 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Graft Versus Host Disease (GvHD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 89: UK Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: UK Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: UK 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 92: UK Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: UK Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: UK 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 95: Spain Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Spain Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Spain 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 98: Spain Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Spain Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Spain 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 101: Russia Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Russia Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Russia 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 104: Russia Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Russia Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Russia 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Rest of Europe Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Rest of Europe 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Rest of Europe Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Rest of Europe 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Graft Versus Host Disease (GvHD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 114: Asia-Pacific Historic Review for Graft Versus Host Disease (GvHD) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Asia-Pacific 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Asia-Pacific Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Asia-Pacific 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Asia-Pacific Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Asia-Pacific 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Graft Versus Host Disease (GvHD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 122: Australia Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Australia Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Australia 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 125: Australia Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Australia Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Australia 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• INDIA
  • Graft Versus Host Disease (GvHD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 128: India Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: India Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: India 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 131: India Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: India Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: India 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 134: South Korea Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: South Korea Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: South Korea 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 137: South Korea Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: South Korea Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: South Korea 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Asia-Pacific Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Asia-Pacific 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Asia-Pacific Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Asia-Pacific 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Graft Versus Host Disease (GvHD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 146: Latin America Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 147: Latin America Historic Review for Graft Versus Host Disease (GvHD) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Latin America 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 149: Latin America Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Latin America Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Latin America 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 152: Latin America Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Latin America Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Latin America 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 155: Argentina Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Argentina Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Argentina 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 158: Argentina Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Argentina Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Argentina 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 161: Brazil Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Brazil Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Brazil 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 164: Brazil Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Brazil Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Brazil 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 167: Mexico Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Mexico Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Mexico 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 170: Mexico Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Mexico Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Mexico 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Rest of Latin America Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Rest of Latin America 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Latin America Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Latin America 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Graft Versus Host Disease (GvHD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 179: Middle East Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 180: Middle East Historic Review for Graft Versus Host Disease (GvHD) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Middle East 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 182: Middle East Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Middle East Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Middle East 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 185: Middle East Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Middle East Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Middle East 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 188: Iran Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Iran Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Iran 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 191: Iran Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Iran Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Iran 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 194: Israel Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Israel Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Israel 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 197: Israel Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Israel Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Israel 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Saudi Arabia Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Saudi Arabia 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Saudi Arabia Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Saudi Arabia 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 206: UAE Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: UAE Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: UAE 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 209: UAE Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: UAE Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: UAE 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Rest of Middle East Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Rest of Middle East 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Rest of Middle East Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Rest of Middle East 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030
• AFRICA
  • Graft Versus Host Disease (GvHD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 218: Africa Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Africa Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Africa 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drug Class - Percentage Breakdown of Value Sales for Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 221: Africa Recent Past, Current & Future Analysis for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Africa Historic Review for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Africa 15-Year Perspective for Graft Versus Host Disease (GvHD) Treatment by Organ Transplant Immunosuppressant Drugs Transplant - Percentage Breakdown of Value Sales for Pancreas, Other Transplant Types, Kidney, Liver, Heart and Lung for the Years 2015, 2025 & 2030

IV. COMPETITION